Romeo R Galang1, Greace Alejandra Avila2, Diana Valencia3, Marcela Daza4, Van T Tong3, Antonio José Bermúdez5, Suzanne M Gilboa3, Angélica Rico5, Jordan Cates3, Oscar Pacheco2, Christina M Winfield3, Franklyn Prieto2, Margaret A Honein3, Liliana J Cortés2, Cynthia A Moore3, Martha L Ospina6. 1. Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: RGalang@cdc.gov. 2. Dirección de Vigilancia y Análisis de Riesgo en Salud Pública, Instituto Nacional de Salud, Bogotá, Distrito Capital, Colombia. 3. Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, United States. 4. Vysnova Partners, Research Division, Bethesda, MD, United States. 5. Dirección de Redes en Salud Pública, Instituto Nacional de Salud, Bogotá, Distrito Capital, Colombia. 6. Dirección General, Instituto Nacional de Salud, Bogotá, Distrito Capital, Colombia.
Abstract
OBJECTIVE: To estimate the prevalence of microcephaly and central nervous system (CNS) defects during the Zika virus (ZIKV) epidemic in Colombia and proportion attributable to congenital ZIKV infection. STUDY DESIGN: Clinical and laboratory data for cases of microcephaly and/or CNS defects reported to national surveillance between 2015 and 2017 were reviewed and classified by a panel of clinical subject matter experts. Maternal and fetal/infant biologic specimens were tested for congenital infection and chromosomal abnormalities. Infants/fetuses with microcephaly and/or CNS defects (cases) were classified into broad etiologic categories (teratogenic, genetic, multifactorial, and unknown). Cases classified as potentially attributable to congenital ZIKV infection were stratified by strength of evidence for ZIKV etiology (strong, moderate, or limited) using a novel strategy considering birth defects unique or specific to ZIKV or other infections and laboratory evidence. RESULTS: Among 858 reported cases with sufficient information supporting a diagnosis of microcephaly or CNS defects, 503 were classified as potentially attributable to congenital ZIKV infection. Of these, the strength of evidence was considered strong in 124 (24.7%) cases; moderate in 232 (46.1%) cases; and limited in 147 (29.2%). Of the remaining, 355 (41.4%) were attributed to etiologies other than ZIKV infection (syphilis, toxoplasmosis, rubella, cytomegalovirus, herpes 1 and herpes 2 viruses only, n = 32 [3.7%]; genetic, n = 16 [1.9%]; multifactorial, n = 42 [4.9%]; unknown, n = 265 [30.9%]). CONCLUSIONS: Fifty-eight percent of cases of microcephaly and/or CNS defects were potentially attributable to congenital ZIKV infection; however, the strength of evidence varied considerably. This surveillance protocol might serve as a model approach for investigation and etiologic classification of complex congenital conditions. Published by Elsevier Inc.
OBJECTIVE: To estimate the prevalence of microcephaly and central nervous system (CNS) defects during the Zika virus (ZIKV) epidemic in Colombia and proportion attributable to congenital ZIKV infection. STUDY DESIGN: Clinical and laboratory data for cases of microcephaly and/or CNS defects reported to national surveillance between 2015 and 2017 were reviewed and classified by a panel of clinical subject matter experts. Maternal and fetal/infant biologic specimens were tested for congenital infection and chromosomal abnormalities. Infants/fetuses with microcephaly and/or CNS defects (cases) were classified into broad etiologic categories (teratogenic, genetic, multifactorial, and unknown). Cases classified as potentially attributable to congenital ZIKV infection were stratified by strength of evidence for ZIKV etiology (strong, moderate, or limited) using a novel strategy considering birth defects unique or specific to ZIKV or other infections and laboratory evidence. RESULTS: Among 858 reported cases with sufficient information supporting a diagnosis of microcephaly or CNS defects, 503 were classified as potentially attributable to congenital ZIKV infection. Of these, the strength of evidence was considered strong in 124 (24.7%) cases; moderate in 232 (46.1%) cases; and limited in 147 (29.2%). Of the remaining, 355 (41.4%) were attributed to etiologies other than ZIKV infection (syphilis, toxoplasmosis, rubella, cytomegalovirus, herpes 1 and herpes 2 viruses only, n = 32 [3.7%]; genetic, n = 16 [1.9%]; multifactorial, n = 42 [4.9%]; unknown, n = 265 [30.9%]). CONCLUSIONS: Fifty-eight percent of cases of microcephaly and/or CNS defects were potentially attributable to congenital ZIKV infection; however, the strength of evidence varied considerably. This surveillance protocol might serve as a model approach for investigation and etiologic classification of complex congenital conditions. Published by Elsevier Inc.
Authors: José Villar; Francesca Giuliani; Tanis R Fenton; Eric O Ohuma; Leila Cheikh Ismail; Stephen H Kennedy Journal: Lancet Date: 2016-02-18 Impact factor: 79.321
Authors: Tolulope Adebanjo; Shana Godfred-Cato; Laura Viens; Marc Fischer; J Erin Staples; Wendi Kuhnert-Tallman; Henry Walke; Titilope Oduyebo; Kara Polen; Georgina Peacock; Dana Meaney-Delman; Margaret A Honein; Sonja A Rasmussen; Cynthia A Moore Journal: MMWR Morb Mortal Wkly Rep Date: 2017-10-20 Impact factor: 17.586
Authors: Carrie K Shapiro-Mendoza; Marion E Rice; Romeo R Galang; Anna C Fulton; Kelley VanMaldeghem; Miguel Valencia Prado; Esther Ellis; Magele Scott Anesi; Regina M Simeone; Emily E Petersen; Sascha R Ellington; Abbey M Jones; Tonya Williams; Sarah Reagan-Steiner; Janice Perez-Padilla; Carmen C Deseda; Andrew Beron; Aifili John Tufa; Asher Rosinger; Nicole M Roth; Caitlin Green; Stacey Martin; Camille Delgado Lopez; Leah deWilde; Mary Goodwin; H Pamela Pagano; Cara T Mai; Carolyn Gould; Sherif Zaki; Leishla Nieves Ferrer; Michelle S Davis; Eva Lathrop; Kara Polen; Janet D Cragan; Megan Reynolds; Kimberly B Newsome; Mariam Marcano Huertas; Julu Bhatangar; Alma Martinez Quiñones; John F Nahabedian; Laura Adams; Tyler M Sharp; W Thane Hancock; Sonja A Rasmussen; Cynthia A Moore; Denise J Jamieson; Jorge L Munoz-Jordan; Helentina Garstang; Afeke Kambui; Carolee Masao; Margaret A Honein; Dana Meaney-Delman Journal: MMWR Morb Mortal Wkly Rep Date: 2017-06-16 Impact factor: 17.586
Authors: Megan R Reynolds; Abbey M Jones; Emily E Petersen; Ellen H Lee; Marion E Rice; Andrea Bingham; Sascha R Ellington; Nicole Evert; Sarah Reagan-Steiner; Titilope Oduyebo; Catherine M Brown; Stacey Martin; Nina Ahmad; Julu Bhatnagar; Jennifer Macdonald; Carolyn Gould; Anne D Fine; Kara D Polen; Heather Lake-Burger; Christina L Hillard; Noemi Hall; Mahsa M Yazdy; Karnesha Slaughter; Jamie N Sommer; Alys Adamski; Meghan Raycraft; Shannon Fleck-Derderian; Jyoti Gupta; Kimberly Newsome; Madelyn Baez-Santiago; Sally Slavinski; Jennifer L White; Cynthia A Moore; Carrie K Shapiro-Mendoza; Lyle Petersen; Coleen Boyle; Denise J Jamieson; Dana Meaney-Delman; Margaret A Honein Journal: MMWR Morb Mortal Wkly Rep Date: 2017-04-07 Impact factor: 17.586
Authors: David L Heymann; Abraham Hodgson; Amadou Alpha Sall; David O Freedman; J Erin Staples; Fernando Althabe; Kalpana Baruah; Ghazala Mahmud; Nyoman Kandun; Pedro F C Vasconcelos; Silvia Bino; K U Menon Journal: Lancet Date: 2016-02-11 Impact factor: 79.321
Authors: Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Jason O Velez; Amy J Lambert; Alison J Johnson; Stephanie M Stanfield; Mark R Duffy Journal: Emerg Infect Dis Date: 2008-08 Impact factor: 6.883
Authors: Shana Godfred-Cato; Suzanne Newton; Laura Adams; Miguel Valencia-Prado; Heather Lake-Burger; Andrea Morrison; Abbey M Jones; Samantha M Olson; Nicole M Roth; Van T Tong; Suzanne M Gilboa; Dana Meaney Delman; Margaret A Honein; Jennifer Erin Staples; Cynthia A Moore Journal: Birth Defects Res Date: 2021-07-30 Impact factor: 2.661